Baylor College of Medicine, Berry Genomics Co. Seek to Improve on Prenatal Genetic Tests
News Jan 07, 2013
BCM’s highly ranked genetics program, led by National Academy of Sciences member Dr. Arthur Beaudet, has been dedicated to providing the medical community with high-quality and comprehensive genetics testing services for over 30 years. BCM’s Medical Genetics Lab has pioneered the development and use of microarray technology for the testing of prenatal/pediatric genetic disorders for more than 50,000 cases.
The microarray testing uses a gene-chip to assess the make-up of chromosomes (organized structures of DNA and proteins that are found in cells) in a particular part of the human genome (genetic blue print). In areas of the genome, there are portions of the genetic material that show imbalances because they are duplicated or deleted abnormally with gains and losses of genetic information that may signal risk for a genetic disorder.
Berry Genomics has developed technologies to screen and test for genetic abnormalities of the fetus by evaluating fetal DNA in maternal plasma. This technology avoids invasive prenatal diagnostic procedures of chorionic villus sampling, which requires samples being taken from the placenta, and/or amniocentesis, where samples are taken from the amniotic sac around the developing fetus.
These procedures have been a source of anxiety and apprehension for expectant mothers, Beaudet said.
"We are committed to improving the diagnostic sensitivity of invasive prenatal testing as exemplified by our participation in a recently published collaborative National Institutes of Health-funded study," said Dr. Arthur Beaudet, chair and professor of molecular and human genetics at BCM. "We are conducting research to enable non-invasive prenatal testing to detect all the conditions currently detected by invasive testing. It is an honor and a privilege to participate in this international collaboration."
"We are very pleased to enter this agreement with Baylor College of Medicine," said Dr. Daixing Zhou, CEO of Berry Genomics. "Non-invasive prenatal testing and microarray technology are rapidly changing the way we detect genetic diseases. By collaborating with Baylor College of Medicine, we are now able to offer the complete solutions for prenatal screening and diagnosis."
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018